Observational Study
Copyright ©The Author(s) 2016.
World J Hepatol. Aug 8, 2016; 8(22): 949-956
Published online Aug 8, 2016. doi: 10.4254/wjh.v8.i22.949
Table 1 Baseline characteristics of 834 patients enrolled
AgeMedian 57 (range 18-78); age > 65: 18.3%
SexMale 64%, female 36%
BMIMean 25.6 (± SD) = 3.2 (range 16-39)
Genotype (%)
1a19.2
1b79.4
11.4
HCV-RNA
HCV-RNA ≤ 10642%
HCV-RNA > 10658%
IL 28B (%)1
TT21.1
CT65.4
CC13.5
Fibrosis (%)
F17.7
F221.1
F333
F438.2
Cirrhosis (CTP%)
A570.8
A623.1
B74.5
B81.6
Previous treatment (%)
Naive24.4
Relapser30.5
Partial responder14.8
Null responder30.3
Comorbidity (%)
Diabetes mellitus11.5
Alcohol12.1
Table 2 Percentage of sustained virological response according to demographics and clinical characteristics
RVR166.5%
HCV-RNA negative at EOT70.1%
Relapse27.3%
SVR 12362.7%
Age
< 50 yr67.4%
50-65 yr63.1%
> 65 yr55.3%
Previous treatment
Naive65.7%
Relapser73.7%
Partial responder67.2%
Null responder55.1%
Fibrosis (%)
F172.7%
F273.4%
F363.3%
F453.4%
F4 > 65 yr43.8%
Table 3 Adverse events (%) and treatment discontinuation
Adverse events (73.9%)
Anemia52.9
Asthenia39.6
Neutro/thrombopenia29.6
Dysgeusia8.6
Psychiatric disorders6.7
Anorectal symptoms5.9
Others (see text)14.9
Treatment discontinuation (122 cases; 14.6%)Number of cases
Rash/Itch36 (29.5%)
Anemia28 (22.9%)
Asthenia18 (14.7%)
Psychiatric disorders6 (5%)
Pancytopenia3 (2.5%)
Neutro/thrombopenia3 (2.5%)
Others (see text)28 (22.9%)

  • Citation: CLEO Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D’Adamo G, D’Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol 2016; 8(22): 949-956
  • URL: https://www.wjgnet.com/1948-5182/full/v8/i22/949.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v8.i22.949